ow.ly
Novo Nordisk STEP Young phase 3 data 40 percent of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
ovo Nordisk today announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years old with obesity. Obesity prevalence is growing in this age group, for whom there are limited clinically tested and approved treatments available when lifestyle modifications are not sufficient.
